Monoclonal Antibody Deal Benchmarks in Rare Disease

Median Upfront

$409M

Range: $200M - $616M

Total Deal Value

$2.2B

Range: $1.3B - $3.1B

Royalty Rate

7.9% - 15.9%

Tiered up to 19.9%

Dev Milestones

$395M

Range: $237M - $553M

Model Your Deal

Market Analysis

Monoclonal Antibody therapies in rare disease have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in rare disease is $409M, with total deal values reaching $2.2B. Development milestones average $395M, while regulatory milestones contribute $449M.

The rare disease monoclonal antibody landscape is characterized by limited competitive intensity per indication but growing platform competition. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for monoclonal antibody rare disease deals range from 7.9% to 15.9% at the base tier, with tiered escalation reaching 11.9%-19.9% on blockbuster sales. Commercial milestones averaging $951M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a monoclonal antibody rare disease licensing deal?

Based on our analysis, Phase 2 monoclonal antibody licensing deals in rare disease average $409M in upfront payments, with a range of $200M to $616M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for monoclonal antibody rare disease transactions?

The median total deal value for Phase 2 monoclonal antibody assets in rare disease is $2.2B, ranging from $1.3B to $3.1B. This includes development milestones ($395M), regulatory milestones ($449M), and commercial milestones ($951M).

What royalty rates are standard for monoclonal antibody deals in rare disease?

Base royalty rates for monoclonal antibody rare disease transactions range from 7.9% to 15.9%, with tiered escalations reaching 11.9%-19.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in monoclonal antibody rare disease deals?

Monoclonal Antibody rare disease deals allocate approximately 81% of total deal value to milestones. Development milestones ($395M) make up the largest share, followed by commercial milestones ($951M) and regulatory milestones ($449M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Monoclonal Antibody Deal Benchmarks in Rare Disease

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Gene Therapy in Rare Disease

Small Molecule in Rare Disease

Monoclonal Antibody in Oncology

Monoclonal Antibody in Neurology

Ready to Calculate Your Deal Terms?